This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug… Read More
Epigenome editing company Tune Therapeutics has showcased new data at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functional cure for chronic Hepatitis B Virus (HBV). Tune presented its lead HBV programme at the 2023 iteration of the… Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
Vesper Bio has initiated a Phase Ib/IIa Proof of Concept (POC) study of its lead candidate VES001 for frontotemporal dementia. The SORT-IN-2 study will evaluate VES001 in patients with mutations in their progranulin-coding gene (GRN), which are causal for FTD(GRN). FTD(GRN) is an early onset degenerative brain disease which is… Read More
Pharmaceutical company Neuraxpharm, focused on the treatment of central nervous system (CNS) disorders, has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US, excluding the… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development?, Sitting Down… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Post-Covid cognitive impairment: a new target for drug development?“, “… Read More
What were the trending topics of the year? Here, we run through DDW’s most read articles of 2024. 10: The future outlook for mRNA therapies In this article for the Spring 2024 issue, DDW Editor Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. 9: Key… Read More
The Longitude Prize series from Challenge Works will launch the Longitude Prize on amyotrophic lateral sclerosis (ALS) in Spring 2025. The next installment in the prize series follows the success of the Longitude Prize on antimicrobial resistance (AMR), won in 2024 by Sysmex Astrego’s PA-100 AST system, and the Longitude… Read More
The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease. “THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric… Read More
Nathan Yee, Senior Director of CMC Portfolio Strategy at Tune Therapeutics, and Lucas Thompson, Senior Director of Research at Tune Therapeutics, discuss the opportunities and challenges in cell therapy. Cell therapy is a transformative medical approach that harnesses living cells as therapeutic agents and has demonstrated the potential to address… Read More
Researchers are closer to understanding what drives the autoimmune disorder Sjögren’s disease, thanks to new discoveries about the role of calcium signalling, regulatory T cells, and interferon. The study, led by scientists at NYU College of Dentistry and NYU Grossman School of Medicine, was published in Science Translational Medicine. Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we approach the end of 2024, it’s great to see that… Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we approach the end of 2024, it’s great to see that… Read More
Biotechnology company Circio Holding has secured approximately NOK 10.7 million (€907.4k) in financing to support the development of its circVec circular mRNA technology. The major allocations in the financing were to existing shareholders Høse AS and Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen) and… Read More
Final draft guidance from the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of elacestrant, the first tailored treatment for locally advanced and metastatic breast cancer with mutations in the ESR1 gene. Specifically, the drug will be available on the NHS to treat post-menopausal women, and… Read More
